Oakmount & Partners investee Intergroup Mining moves closer to Nasdaq IPO with SEC filing

Oakmount & Partners Ltd managing director Glenn King talked with Proactive's Stephen Gunnion about the progress investee company Intergroup Mining has made toward its planned listing on the Nasdaq stock exchange. King explained that the submission of legal and accounting documentation to the US Securities and Exchange Commission (SEC) marks a “significant milestone” for Intergroup Mining. “It now means that the company, from a tangible perspective, is just one stage closer to its debut listing,” he said. He noted that while the SEC now enters a review phase, Intergroup can respond to any questions and continue progressing toward its IPO. King also outlined the key compliance steps remaining and highlighted the importance of demonstrating strong financials, clear business plans, and limited share dilution. From an investor perspective, King said a US listing would deliver strategic benefits. “You’re on a notable tier one exchange with deep pools of liquidity,” he noted, adding that it may also position Intergroup as an acquisition target in the coming years. He added that Intergroup Mining produces kaolin, metakaolin, and is also positioned to begin gold production, noting that the project is considered a "legacy mine" with a life expectancy of more than 100 years. Updates are expected around late January or early February, depending on SEC feedback. For more interviews like this, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe, and turn on notifications for future content. #IntergroupMining #NasdaqIPO #OakmountPartners #MiningStocks #Kaolin #GoldMining #Metakaolin #USListing #SECfiling #InvestorUpdates #IPOProcess #CapitalMarkets #ProactiveInvestors

Dekiln CEO Dr Aled Roberts talked with Proactive's Stephen Gunnion about the company’s breakthrough in sustainable ceramic tile production and how £3 million in funding from the Royal Academy of Engineering’s Green Future Fellowship program will help scale the technology. Roberts explained that conventional ceramic tiles have a high carbon footprint due to the energy-intensive kiln-firing process. Dekiln has developed an alternative by mimicking natural processes seen in seashells and tooth enamel, creating tiles that function and feel like ceramics without requiring high-temperature firing. “Our materials are made with very high recycled content,” said Roberts. The tiles are manufactured using recycled gypsum, plastics, and calcium sulfate, combined with a bio-based active ingredient. This not only lowers energy input but significantly reduces carbon emissions in the manufacturing process. The funding will support Dekiln’s transition from lab-scale production—currently at one square metre of tiles per day—to commercial-scale manufacturing. The company has recently moved into a new facility and upgraded to an entry-level commercial press, representing the first step in its scale-up journey. It now aims to work with a UK-based industrial partner to build a pilot plant. For more insights into Dekiln’s progress and the Frontier IP Group, PLC (LSE:FIPP) innovative portfolio, visit Proactive’s YouTube channel, and don’t forget to like this video, subscribe, and enable notifications for updates on future interviews and company developments. #Dekiln #SustainableMaterials #GreenTechnology #NetZero #RoyalAcademyOfEngineering #ClimateTech #RecycledMaterials #CeramicInnovation #LowCarbon #Cleantech

M2i Global CEO Alberto Rosende joined Steve Darling from Proactive to provide an update on the company’s strategic initiatives, including progress on its merger with Volato and a new offtake agreement with Next-Gen. Rosende confirmed that the long-anticipated merger with Volato is moving forward after delays caused by a recent government shutdown. “We were able to push it out quickly,” he said, referencing the company’s SEC filing response. The shareholder meeting to approve the merger is scheduled for February 26th, 2026, with the company aiming to close the deal by the end of the first quarter. This milestone is expected to strengthen M2i Global’s software development capabilities, particularly in applications supporting critical mineral supply chains. The CEO also shared details about a new partnership with Next-Gen, which operates a proprietary cathode material process. The facility in Australia will be the first of its kind outside China, and M2i Global has secured an exclusive offtake agreement for the material, expected to begin delivery in approximately two years. Rosende described the development as “really exciting news that we’ll be able to bring that to the United States,” underscoring the strategic importance of securing a stable, non-China-based supply of cathode materials for the North American market. Looking ahead to 2026, Rosende emphasized Volato’s critical role in the company’s broader Critical Minerals Reserve project. Volato will provide software solutions for material tracking, inventory management, and integration with partner operations. A pilot program is planned to validate the technology, ensuring seamless coordination across the supply chain and providing real-time analytics for strategic decision-making. Rosende concluded that these developments position M2i Global to enhance its operational capabilities, secure critical supply sources, and expand its footprint in the rapidly growing market for advanced battery materials and critical minerals. #proactiveinvestors #m2iglobalinc #otcqb #mtwo #CriticalMinerals #SupplyChainSecurity #StrategicMinerals #USDefense #EconomicSecurity #BlockchainLogistics #CriticalMinerals #NevadaMining #parslee #volato #gallium

Replenish Nutrients CEO Neil Wiens joined Steve Darling to outline the company’s transition from development into full commercialization, highlighted by strategic licensing agreements and a significant partnership in the United States. Wiens described 2025 as a pivotal transformation year for Replenish Nutrients. During this period, the company successfully completed its proof-of-concept phase, finalized key intellectual property filings, and moved into commercial-scale operations. “We are physically into that next phase where the licensing deals are real,” Wiens said, emphasizing that the business is now executing on its commercialization strategy rather than preparing for it. A central focus of the discussion was Replenish Nutrients’ recently announced U.S. licensing agreement with Farmers Union Enterprises. The agreement provides the company with access to approximately 70 million acres of farmland, representing a substantial commercial opportunity. Wiens highlighted the favorable timing of the deal, noting its alignment with a newly announced US$700 million USDA regenerative agriculture program. He described the timing as “absolutely fantastic,” as policy support and grower interest in soil health solutions continue to accelerate. Operationally, Wiens confirmed that the company’s Minnesota-based production facility is on track to become operational by June. In parallel, Replenish Nutrients is actively engaged in discussions to expand its footprint into four additional U.S. states. Beyond North America, the company is also evaluating opportunities in Brazil, citing strong synergies in nutrient usage and alignment with its existing supply chain partner. Wiens reiterated that farmer return on investment remains the cornerstone of adoption. “If I can get soil health plus keep my yield the same or better and also start decreasing my fungicide and pesticide use – I win as a farmer,” he said, underscoring the value proposition Replenish aims to deliver to growers. Looking ahead to 2026, Replenish Nutrients plans to scale its global presence while maintaining its operational and corporate base in Canada, positioning the company to benefit from the growing global focus on regenerative agriculture and sustainable food production. #proactiveinvestors #replenishnutrientsholdingscorp #cse #erth #otc #vvivf #RegenerativeAgriculture #FertilizerInnovation #SustainableFarming #CropGrowth #NeilWiens #AgricultureNews #Farming2025 #ProactiveInvestors #SustainableSolutions #Agritech #FertilizerInnovation #MJAgSolutions #PelletFertilizer #ProbioticSoil #BeisekerFacility #CanadianAgriculture

ProPhase Labs CEO Ted Karkus joined Steve Darling from Proactive to announce that the company has entered into a non-binding Letter of Intent (LOI) regarding a proposed reverse merger transaction with Advanced Biological Laboratories (ABL), a European biotechnology and MedTech group. Under the proposed structure, Advanced Biological would become the majority owner of the combined public entity, while ProPhase’s existing operations would continue as sister companies to a newly formed U.S. subsidiary expected to remain under ProPhase’s current management team. Karkus emphasized that the transaction remains subject to the execution of definitive agreements, regulatory approvals, and board authorization. However, the parties have discussed a preliminary, non-binding valuation framework that could imply an enterprise value of up to approximately US$30 million for ProPhase’s legacy business. This framework is intended to provide a basis for ongoing negotiations rather than a final valuation. As outlined in the LOI, and subject to applicable law and final documentation, ProPhase Labs may declare a special cash dividend of up to US$10 million payable to shareholders of record on a date to be determined. Importantly, any such dividend would be distributed separately and would not be part of the merged operating company. In addition, all Crown Medical Collections receivables are expected to be carved out and retained exclusively for the benefit of current ProPhase shareholders, further preserving value for existing investors. Advanced Biological Laboratories would contribute its global biotechnology and MedTech infrastructure to the combined company, including advanced health data processing platforms, cloud-based computing capabilities, and access to international financing resources. The combination is intended to create a more diversified healthcare technology platform with expanded global reach, while allowing ProPhase to unlock value for shareholders through potential cash distributions and retained assets. #proactiveinvestors #prophaselabs #nasdaq #prph #biotech #genomics #genomesequencing #ProPhaseLabs #AdvancedBiologicalLaboratories #ReverseMerger #LOI #Biotechnology #MedTech #HealthcareTechnology #StrategicTransaction #ShareholderValue #SpecialDividend #NasdaqListed #GlobalHealthcare #HealthData #CloudComputing #LifeSciences #MergersAndAcquisitions

Cabbacis CEO Joe Pandolfino joined Steve Darling from to discuss the company’s strategic preparations to enter the U.S. market with its proprietary low-nicotine tobacco products. Cabbacis is a federally licensed tobacco product manufacturer with a robust intellectual property portfolio that includes 35 issued patents worldwide, covering its iBlend™ cigarettes and vaporizer pod technology. The company operates out of a manufacturing facility in Niagara Falls, New York, and is led by a management team that brings more than 50 years of combined experience in the tobacco industry. Pandolfino explained that iBlend™ products have been specifically engineered to align with anticipated regulatory changes in the United States. He noted that the U.S. Food and Drug Administration is advancing a rule that could require a reduction of nicotine levels in all cigarettes sold in the country by approximately 95%. “The FDA is moving forward a rule which would mandate the reduction of nicotine in all cigarettes sold in the United States by about 95%,” Pandolfino said, positioning iBlend™ as a potential solution for a post-regulation tobacco market. Cabbacis’ strategy centers on improving consumer acceptance of very low nicotine cigarettes, which multiple peer-reviewed studies have shown can significantly reduce smoking frequency and nicotine dependence. Pandolfino highlighted that the company’s proprietary blend incorporates hemp alongside tobacco, a formulation that internal focus group research indicates is more appealing to smokers than traditional very low nicotine products. Looking ahead, Cabbacis plans to conduct additional studies in the first quarter of 2026 to support regulatory submissions. The company is targeting the submission of a Pre-Market Tobacco Application (PMTA) to the FDA for its iBlend™ products in the first half of 2026. Pandolfino told Proactive that achieving FDA authorization would mark a major milestone and could position Cabbacis as an early mover in a rapidly evolving, regulation-driven U.S. tobacco landscape. #proactiveinvestors #cabaccis #otcqb #cabi #Cabbacis #iBlend #LowNicotine #TobaccoInnovation #FDARegulation #PMTA #NicotineReduction #HarmReduction #TobaccoIndustry #SmokingCessation #RegulatoryStrategy #IntellectualProperty #PatentedTechnology #USMarketEntry #ConsumerHealth

Happy Creek Minerals CEO Steve Gray joined Steve Darling from Proactive to share details of the company’s latest assay results from its 2025 diamond drilling program at the Fox Tungsten Project in British Columbia. The recently completed program focused on expanding the known tungsten mineralization at the Ridley Creek (RC) and BN zones, two of the project’s most prospective target areas. During September and October, Happy Creek completed a total of 18 diamond core drill holes at the Fox Project, drilling an aggregate 2,176 metres. The primary objective of the program was to test extensions of known calc-silicate horizons that host tungsten mineralization and to better define the geometry and continuity of these zones beneath areas of limited surface exposure. Gray told Proactive that drilling at the Ridley Creek zone successfully confirmed strong continuity of the calc-silicate horizon and expanded the mineralized system to the southwest. Importantly, the mineralization remains clearly open to the west beneath Deception Mountain, highlighting significant potential for further resource growth. One of the standout results from the RC zone came from hole F25-13, which intersected 1.18 metres grading an impressive 6.83% WO₃ at a downhole depth of 31.2 metres. At the BN zone, drilling on the northwest side intersected multiple calc-silicate horizons, supporting a stacked-layer geological model. One of these mineralized horizons was intersected at a depth of approximately 200 metres below surface, indicating the system extends well beyond previously tested depths. Results from hole F25-16 included 1.00 metre grading 0.88% WO₃ from 105.0 metres downhole, as well as a deeper intercept of 1.65 metres grading 0.57% WO₃ from 218.3 metres downhole. According to Gray, the 2025 drilling program clearly demonstrates that the calc-silicate horizons and associated tungsten mineralization at both the RC and BN zones remain open to the west and north beneath Deception Mountain. The results also point to the potential for additional, yet-to-be-discovered horizons at depth, reinforcing the Fox Project’s upside as a growing tungsten system. Happy Creek plans to incorporate the new assay and geological data into its ongoing interpretation work as it evaluates next steps for further drilling and resource expansion at the Fox Tungsten Project. #proactiveinvestors #happycreekmineralsltd #tsxv #hpy #Tungsten #WO3 #CriticalMinerals #BritishColumbiaMining #DrillResults #DiamondDrilling #MineralExploration #ResourceExpansion #CalcSilicate #TungstenMining #StrategicMetals #ExplorationSuccess #MiningNews #ProactiveInvestors

Ilika CEO Graeme Purdy joined Steve Darling from Proactive to announce that the company has begun shipping prototype Stereax M300 solid-state batteries to customers, marking a significant commercial milestone for the business. The initial shipments represent the first delivery of the M300 product and will be allocated to the 21 customers that currently make up Ilika’s existing order book. Many of these customers have already evaluated earlier-generation Stereax batteries supplied from Ilika’s UK pilot production line, and the new prototype deliveries are intended to support further validation and system-level integration. In parallel, a portion of the initial M300 batches will be retained by Ilika for its extensive internal testing programme. This programme is designed to generate a broader and more robust body of performance data aligned with demanding use cases, particularly within active implantable medical devices. Purdy told Proactive that the potential applications for the Stereax M300 span a wide range of implantable and wearable medical technologies. These include powering implanted sensors, neurostimulators, orthopaedic implants, orthodontic wearables, and ophthalmology devices. He explained that Stereax’s small footprint, combined with enhanced charging capability, makes it especially well suited for AIMDs. Key benefits of the Stereax technology include reduced surgical time, greater flexibility in placing implants closer to the point of therapy, long operational life, and the convenience of user recharging at home. In addition, the battery’s ability to support Bluetooth radio functionality opens the door to advanced connected medical applications. As part of the commercialization process, Ilika and its strategic manufacturing partner, Cirtec Medical Corp, will actively gather feedback from this initial customer group. The insights gained will be used to verify customer experience and performance expectations before scaling up production. This latest milestone advances the 10-year manufacturing agreement signed in August 2023, under which Cirtec Medical, a leading US-based medical device manufacturer, will produce Ilika’s full Stereax battery portfolio. The commencement of prototype shipments represents a key step toward broader commercial deployment of Ilika’s solid-state battery technology in medical markets. #proactiveinvestors #ilika #aim #ika #goliathautomatedline #SolidStateBatteries #Stereax #GoliathBattery #BatteryTech #GraemePurdy #EVBatteries #EnergyStorage #CirtecMedical #JaguarLandRover #UniversityOfOxford #ProactiveInvestors

Regan Capital CIO Skyler Weinand joined Steve Darling from Proactive to share news about the dynamics of the fixed income markets, interest rates, and mortgage-backed securities. Weinand outlined Regan Capital’s focus on U.S. mortgage-backed securities, noting the company manages around $3.6 billion across mutual funds, ETFs, and a UCITS ETF for non-U.S. investors. “Mortgages are about $13.5 trillion outstanding,” Weinand said, emphasizing the scale of the U.S. mortgage market and the challenges retail investors face accessing it directly. He discussed how recent Federal Reserve rate cuts have not lowered long-term interest rates. In fact, the yield on longer-term bonds and mortgage rates have increased. Weinand stated, “Mortgage rates are actually higher today than they were last September.” He cautioned that loose financial conditions, robust corporate balance sheets, and rising equity markets suggest rates could move higher, even if the Fed implements more cuts. He noted growing corporate debt issuance, with examples like Google’s 50-year bond at a 5.7% coupon. For investors, Weinand recommended focusing on short-duration and floating-rate securities, especially those backed by U.S. government guarantees, which can offer higher yields with lower volatility. #FixedIncome #InterestRates #MortgageBonds #SkylerWeinand #ReganCapital #BondMarket #ETFs #ShortDurationBonds #FederalReserve #FinancialMarkets #InvestmentStrategy #FloatingRate #ProactiveInvestors

Standard Uranium CEO Jon Bey joined Steve Darling from Proactive to discuss the company’s operational progress throughout 2025 and outline its strategic roadmap heading into 2026, highlighting a year marked by successful capital raising, advancing exploration programs, and the expansion of its joint venture portfolio. Bey noted that Standard Uranium raised nearly C$7.0 million during 2025, providing the financial foundation to advance multiple exploration initiatives across its project portfolio. A significant portion of that capital has been allocated to the Davidson River project, which is now fully funded and preparing for the largest drill program in the project’s history. Drilling at Davidson River is scheduled to begin in late May 2026 and is expected to be a major catalyst for the company. One of the year’s key developments was the return of 100% ownership of the Sun Dog project to Standard Uranium after joint venture partner Arrow Energy was unable to meet its funding commitments. Bey explained that this outcome has positioned the company to re-engage the market, confirming that multiple confidentiality agreements have already been signed with interested joint venture partners. Subject to final agreements, drilling at Sun Dog is expected to resume in late summer 2026. The company also continued to advance its project generator business model by securing new joint venture agreements. Standard Uranium entered into a partnership with Aventis on the Corvo project and a separate agreement with Collective Metals on the Rocas project. Both projects are on track to begin drilling in the first quarter of 2026, further diversifying the company’s near-term exploration pipeline. Looking ahead, Bey confirmed that Standard Uranium’s full management and technical team will attend the Vancouver Resource Investment Conference in January 2026. The company plans to meet with investors and stakeholders at the event to provide updates on its exploration plans and outline anticipated catalysts for the year ahead. #proactiveinvestors #standarduraniumltd #tsxv #stnd #otcqb #sttdf #mining #uranium #corvoproject #UraniumExploration #AthabascaBasin #DavidsonRiver #MiningInnovation #Geophysics #AmbientNoiseTomography #ResourceInvesting #FleetSpace #UraniumDiscovery #MiningNews